Shruti Jolly, MD

Antonia SJ et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med 2018;379(24):2342-50. Abstract

Antonia SJ et al. Durvalumab after chemoradiotherapy in stage III non-small cell lung cancer. N Engl J Med 2017;377(20):1919-29. Abstract

Bradley JD et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small cell lung cancer (RTOG 0617): A randomized, two-by-two factorial phase 3 study. Lancet Oncol 2015;16(2):187-99. Abstract

Golden EB, Formenti SC. Is tumor (R)ejection by the immune system the "5th R" of radiobiology? Oncoimmunology 2014;3(1):e28133. Abstract

Ko EC et al. The integration of radiotherapy with immunotherapy for the treatment of non-small cell lung cancer. Clin Cancer Res 2018;24(23):5792-806. Abstract

Corey J Langer, MD

Deng L et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest 2014;124(2):687-95. Abstract

Durm GA et al. Phase II trial of concurrent chemoradiation with consolidation pembrolizumab in patients with unresectable stage III non-small cell lung cancer: Hoosier Cancer Research Network LUN 14-179. ASCO 2018;Abstract 8500.

Gray JE et al. Three-year overall survival update from the PACIFIC trial. ASCO 2019;Abstract 8526.

Jabbour SK et al. Prospective phase I multi-institutional trial of PD-1 blockade with pembrolizumab during concurrent chemoradiation for locally advanced, unresectable non-small cell lung cancer. ASCO 2019;Abstract 8511.

Twyman-Saint Victor C et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 2015;520(7547):373-7. Abstract

Zeng J et al. Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int J Radiat Oncol Biol Phys 2013;86(2):343-9. Abstract

Jyoti D Patel, MD

Brahmer JR et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2018;36(17):1714-68. Abstract

Nishino M et al. Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: A systematic review and meta-analysis. JAMA Oncol 2016;2(12):1607-16. Abstract

Peters S et al. Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer — The ETOP NICOLAS trial. Lung Cancer 2019;133:83-7. Abstract

Weber JS et al. Safety profile of nivolumab (NIVO) in patients (pts) with advanced melanoma (MEL): A pooled analysis. ASCO 2015;Abstract 9018.

Billy Wiseman Loo Jr, MD, PhD

A phase I multicenter study of immunotherapy in combination with chemoradiation in patients with advanced solid tumors (CLOVER). NCT03509012

A phase II trial evaluating the safety and efficacy of the addition of concurrent anti-PD 1 nivolumab to standard first-line chemotherapy and radiotherapy in locally advanced stage IIIA/B non-small cell lung carcinoma. NCT02434081

A phase 2 trial of pembrolizumab (MK-3475) in combination with platinum doublet chemotherapy and radiotherapy for participants with unresectable, locally advanced stage III non-small cell lung cancer (NSCLC) (KEYNOTE-799). NCT03631784

A phase III, randomized, placebo-controlled, double-blind, multi-center, international study of durvalumab given concurrently with platinum-based chemoradiation therapy in patients with locally advanced, unresectable non-small cell lung cancer (stage III) (PACIFIC2). NCT03519971

A randomized phase II study of pembrolizumab (MK-3475) as maintenance therapy in patients with unresectable stage III non-small cell lung cancer treated with definitive chemo-radiotherapy. NCT03379441

A randomized phase III comparison of standard-dose (60 Gy) versus high-dose (74 Gy) conformal radiotherapy with concurrent and consolidation carboplatin/paclitaxel +/- cetuximab (IND #103444) in patients with stage IIIA/IIIB non-small cell lung cancer. NCT00533949

Bauml JM et al. Pembrolizumab after completion of locally ablative therapy for oligometastatic non-small cell lung cancer: A phase 2 trial. JAMA Oncol 2019;[Epub ahead of print]. Abstract

Bradley JD et al. Long-term results of RTOG 0617: A randomized phase 3 comparison of standard dose versus high dose conformal chemoradiation therapy +/- cetuximab for stage III NSCLC. Proc ASTRO 2017;Abstract 227.

DETERRED: PD-L1 blockadE To Evaluate the Safety of lung canceR therapy using carboplatin, paclitaxel, and radiation combinEd with MPDL3280A. NCT02525757

Dieleman EMT et al. Concurrent daily cisplatin and high-dose radiation therapy in patients with stage III non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2018;102(3):543-51. Abstract

Durvalumab and consolidation SBRT following chemoradiation for locally advanced stage III non-small cell lung. NCT03589547

Formenti SC et al. Radiotherapy induces responses of lung cancer to CTLA-4 blockade. Nat Med 2018;24(12):1845-51. Abstract

Lin SH et al. DETERRED: PD-L1 blockade to evaluate the safety of lung cancer therapy using carboplatin, paclitaxel, and radiation combined with MPDL3280A (atezolizumab). Proc ASCO 2017;Abstract 3064.

Moving PD-1 blockade with pembrolizumab into concurrent chemoradiation for locally advanced non-small cell lung cancer. NCT02621398

Phase I trial of accelerated or conventionally fractionated radiotherapy combined with MEDI4736 (durvalumab) in PD-L1 high locally advanced non-small cell lung cancer (NSCLC) (ARCHON-1). NCT03801902

Phase II study of consolidation immunotherapy with nivolumab and ipilimumab or nivolumab alone following concurrent chemoradiotherapy for unresectable stage IIIA/IIIB non-small cell lung cancer (NSCLC): BTCRC-LUN16-081. NCT03285321

Phase II trial of induction immunotherapy with atezolizumab for patients with unresectable stage IIIA and IIIB NSCLC eligible for chemoradiotherapy with curative intent. NCT03102242

Phase III randomized trial comparing overall survival after photon versus proton chemoradiotherapy for inoperable stage II-IIIB NSCLC. NCT01993810

Radiation and chemotherapy with ipilimumab followed by nivolumab for patients with stage III unresectable NSCLC. NCT03663166

Randomized, double-blinded phase III trial of cisplatin and etoposide plus thoracic radiation therapy followed by nivolumab/placebo for locally advanced non-small cell lung cancer. NCT02768558

The Selective Personalized Radio-Immunotherapy for locally advanced NSCLC Trial (SPRINT). NCT03523702

Theelen WSME et al. Effect of pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumor response in patients with advanced non-small cell lung cancer: Results of the PEMBRO-RT phase 2 randomized clinical trial.  JAMA Oncol 2019;[Epub ahead of print]. Abstract

Walraven I et al. Long-term follow-up of patients with locally advanced non-small cell lung cancer receiving concurrent hypofractionated chemoradiotherapy with or without cetuximab. Radiother Oncol 2016;118(3):442-6;[Epub ahead of print]. Abstract